Royalty Pharma Deals Aren’t Just For Start-Ups Anymore
Wall Street Journal | By Brian Gormley
Selling royalty interests in health care products was once a vehicle mainly for universities, inventors and smaller drug and medical-technology companies. But increasingly, big companies are getting into the act.